期刊文献+

血站实验室献血者HCV抗体检验报告新模式探讨 被引量:4

A study on optimizing reporting process for hepatitis C virus antibody test for blood donors in blood center' laboratory
下载PDF
导出
摘要 目的评估血站日常抗-HCV间接法酶联免疫吸附实验检测结果的准确性,探讨如何转换抗-HCV报告流程,保护献血者的积极性及珍贵的血液资源。方法使用上海科华间接法丙型肝炎试剂盒(试剂A)、北京万泰间接法丙型肝炎试剂盒(试剂B)对116份标本进行间接法酶联免疫检测,测定结果为阳性或灰区的标本,使用确认试剂进一步检测,确定其真实结果,统计本地区丙型肝炎确认结果与双试剂检测结果的对应分布情况。两种抗-HCV试剂对116份标本的检测采用配对χ2检验,对两种试剂的检验结果采用一致性检验。结果两种间接法试剂对116例标本的检测结果,差异具有统计学意义(P=0.04),而两种试剂一致性较差,双试剂强阳性标本、弱阳性标本的假阳性率分别为0、35.7%;两种试剂的单试剂阳性标本、灰区标本的假阳性率分别为A试剂:94.3%、100%;B试剂:84.2%和88.9%。结论间接法试剂假阳性率较高,特异性较差,国产间接法试剂之间存在较大差异,应对原丙型肝炎报告方式进行修改,对弱阳性标本应进行进一步的确证实验以保护献血者积极性。 Objective To assess the accuracy of indirect enzyme- linked immunosorbent assay( ELISA) for hepatitis C virus( HCV) antibody as a routine test in the blood center,discuss how to optimize the reporting process for HCV antibody,and protect donors' enthusiasm and precious blood resources. Methods A total of 116 samples were screened by two indirect anti- HCV ELISA kits available from Shanghai Kehua( reagent A) and Beijing Wantai( reagent B),respectively. Samples that yielded positive results or gray- zone results were further validated using a confirmation reagent to establish definitive results and compare confirmed positive results and the results with the two reagents for indirect ELISA. Differences in the ELISA results of the 116 samples between the two anti- HCV reagents were compared using the paired chi- square test and the agreement between the results with the two reagents were compared using the Kappa test. Results There were significant differences in the test results between the two reagents used for indirect ELISA( P = 0. 04),but the two reagents varied greatly from each other. The false positive rates of samples strongly or weakly positive with both reagents were 0 and 35. 7%,respectively;the false positive rates of samples positive with either reagent or samples with gray- zone results were 94. 3% and 100% for reagent A and84. 2% and 88. 9% for reagent B. Conclusion Reagents used for indirect ELISA have high false positive rates and poor specificity and considerable differences exist between homemade indirect reagents. The existing HCV reporting process should be modified. Weakly positive specimens should be further validated by a confirmatory test to protect blood donors' enthusiasm.
作者 甄志军
机构地区 邢台市中心血站
出处 《临床肝胆病杂志》 CAS 2015年第8期1275-1277,共3页 Journal of Clinical Hepatology
关键词 肝炎抗体 丙型 酶联免疫吸附测定 输血传播病毒 hepatitis C antibodies enzyme-linked immunosorbent assay torque teno virus
  • 相关文献

参考文献8

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2中华人民共和国卫生部卫医政发(2012]1号血站技术操作规程[S/OL].[2012-02-28]http://www.gov.cn/gzdt/2012-02/28/content-2078097htm.
  • 3李瑞兰,赵莉,孙树起.国内部分地区献血者抗-HCV阳性率调查[J].中国输血杂志,1994,7(2):98-99.
  • 4中华人民共和国国家卫生和计划生育委员会.丙型病毒性肝炎诊断标准[S/OL].卫生部政策法规司,[2009-07-29]zwgkzt/s9491/200907/41980shtmlhttp://www.nhfpc.gov.cn/-1.
  • 5COLIN C, LANOIR D, TOUZET S, et al. Senstivity and spe- cificity of third - generation hepatitis C virus antibody detec- tion assay: an analysis of the literature[J]. . J Viral Hepat, 2001, 8(2) : 87 -95.
  • 6KATO N. Molecular virology of hepatitis C virus[J]. Acta Med Okayama, 2001,55(3) : 133 -159.
  • 7谢立,吴晓东.丙型肝炎病毒检测方法的研究进展及其临床意义[J].世界华人消化杂志,2005,13(7):884-886. 被引量:56
  • 8朱鹏,陈晴,王丽,王宇明.欧洲肝病学会临床实践指南:HCV感染的管理(推荐意见)[J].临床肝胆病杂志,2014,30(2):109-112. 被引量:24

二级参考文献23

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 3Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 4Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 5Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 6Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 7Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 8Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 9Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 10Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.

共引文献807

同被引文献25

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部